Caleb ran a subscription business through a pandemic-era turnaround before returning to venture, and he once turned down his own healthcare startup idea because he didn't think it could reach true venture scale—experiences that shape how closely he checks whether a founder's business actually fits venture investing. At Bison he focuses on AI in physical form, like robots and machinery, argues that deep tech can be safer to back than software once the science works and a company proves engineering and commercial traction, and encourages founders—especially in TechBio—to build revenue-generating platforms and lean into their own strengths rather than default to a standard therapeutics path.